Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, shared a post on X:
“IBI363 (PD-1/IL-2α-bias), co-development, co-commercialize it in the U.S, commercialization rights outside Greater China and the U.S.
IBI343 (CLDN18.2 ADC), rights outside China.
IBI3001 (EGFR/B7H3 ADC), option for the rights outside China.”
You can also read Findings from a first-in-human phase I study investigating IBI363 – ESMO
